Marstacimab

DelveInsight's 'Hemophilia B Pipeline Insight, 2024' report details the global Hemophilia B treatment market, including clinical trials, therapies, and company developments. Key companies and therapies in various stages of development are highlighted, along with market drivers and barriers.

Pfizer announces positive Phase 3 results for hemophilia A gene therapy candidate giroctocogene fitelparvovec, showing significant reduction in annualized bleeding rate post-infusion and generally well-tolerated profile.

Pfizer's Q1 2024 earnings call highlighted a solid start to the year, with a focus on executing five strategic priorities: achieving world-class oncology leadership, delivering pipeline innovation, maximizing new product performance, expanding margins, and enhancing shareholder value. The company reported operational revenue growth of 11% excluding COVID products, with notable progress in oncology and other key areas. Pfizer also discussed its cautious optimism for the year ahead, emphasizing disciplined execution and strategic investments to drive growth and shareholder returns.